## **Product** Data Sheet

## **Saredutant**

Cat. No.: HY-106910

CAS No.: 142001-63-6

Molecular Formula:  $C_{31}H_{35}Cl_2N_3O_2$ Molecular Weight: 552.53

Target: Neurokinin Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 250 mg/mL (452.46 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8099 mL	9.0493 mL	18.0986 mL
	5 mM	0.3620 mL	1.8099 mL	3.6197 mL
	10 mM	0.1810 mL	0.9049 mL	1.8099 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.76 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility:  $\ge$  2.08 mg/mL (3.76 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.76 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	Saredutant is a selective NK2 receptor antagonist.	
IC <sub>50</sub> & Target	NK2	
In Vivo	Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Saredutant has dose-dependent effects on swim test immobility, with the low dose of 1 mg/kg having no effect and the doses of 3 and 10 mg/kg significantly reducing immobility $^{[1]}$ .	

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **PROTOCOL**

# Animal Administration [1]

#### Rats<sup>[1]</sup>

In the first experiment the dose-related effects of Saredutant are investigated. The Flinders Sensitive Line (FSL) rats (n=8) are treated with one of the following: vehicle (carboxymethylcellulose-CMC) or 1, 3, or 10 mg/kg Saredutant, or 5 mg/kg Desipramine as a positive control. Saredutant is injected at 1 mL/kg. The Flinders Resistant Line (FRL) rats are given CMC or 3 mg/kg Saredutant. All injections are i.p. and are given for 14 consecutive days. Approximately 22 h after the last injections the rats are placed in the social interaction chamber with similarly treated rats for a 5-min recording. Then about 2 h later the rats are individually tested in the forced swim test for a single 5-min session<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

- Respir Physiol Neurobiol. 2022 Jul 26;103952.
- Authorea. 2023 Aug 14.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

[1]. Overstreet DH, et al. Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with Desipramine in an animal model of depression. Pharmacol Biochem Behav. 2010 Aug;96(2):206-10.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA